Follow Nautilus Biotechnology to never miss an important update.
Nautilus lost about 12 cents per share last quarter, which was slightly better than the 14 cent loss analysts expected. As a development-stage company, it still has no revenue, but it ended the quarter with a new partnership. It joined a research group funded by ARPA-H, a federal agency that backs high-risk health projects, to help study the proteins that drive Alzheimer's and cancer.
This partnership is a useful win because it provides up to 6 million dollars in funding and puts the company's Voyager platform in the hands of major researchers. For a business that is currently spending more cash than it brings in, these grants help extend its runway while it works toward a full commercial launch in 2027.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Roth Capital set a price target of 3.50 dollars for Nautilus. This is a routine move that sits near the average analyst target of 4 dollars. Since the firm did not change its overall rating on the stock, this update does not signal a major shift in how Wall Street sees the company's prospects.
Source: Roth Capital
Management consistently sets a low bar and clears it, delivering eight straight quarters of slightly smaller losses than expected. This shows a disciplined control over spending while the company works toward its first product launch.
| Expectation | |
|---|---|
| EPS | $-0.15 |
| Revenue | $0M |
Follow Nautilus Biotechnology to get the latest and most important updates.
Follow NAUT